Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DRIO NASDAQ:DXR NASDAQ:IRIX NASDAQ:NYXH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDRIODarioHealth$7.90+12.9%$7.24$5.84▼$17.74$51.19M1.0913,999 shs181,889 shsDXRDaxor$11.03+4.9%$10.42$8.56▼$14.76$61.36M0.262,397 shs335 shsIRIXIRIDEX$0.92$1.09$0.87▼$1.65$15.93M0.6343,419 shs18,731 shsNYXHNyxoah$1.53-0.6%$2.01$1.26▼$8.59$59.69M1.61183,075 shs195,768 shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDRIODarioHealth+3.40%+7.20%+1.01%-5.53%-50.35%DXRDaxor-7.01%+0.66%+7.57%+4.11%+14.54%IRIXIRIDEX-1.13%-14.48%-20.08%-12.85%-27.37%NYXHNyxoah-1.28%-2.53%-3.75%-49.84%-80.60%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDRIODarioHealth$7.90+12.9%$7.24$5.84▼$17.74$51.19M1.0913,999 shs181,889 shsDXRDaxor$11.03+4.9%$10.42$8.56▼$14.76$61.36M0.262,397 shs335 shsIRIXIRIDEX$0.92$1.09$0.87▼$1.65$15.93M0.6343,419 shs18,731 shsNYXHNyxoah$1.53-0.6%$2.01$1.26▼$8.59$59.69M1.61183,075 shs195,768 shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDRIODarioHealth+3.40%+7.20%+1.01%-5.53%-50.35%DXRDaxor-7.01%+0.66%+7.57%+4.11%+14.54%IRIXIRIDEX-1.13%-14.48%-20.08%-12.85%-27.37%NYXHNyxoah-1.28%-2.53%-3.75%-49.84%-80.60%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDRIODarioHealth 2.00Hold$10.5032.91% UpsideDXRDaxor 2.50Moderate BuyN/AN/AIRIXIRIDEX 2.00Hold$3.00227.83% UpsideNYXHNyxoah 2.25Hold$5.96289.71% UpsideCurrent Analyst Ratings BreakdownLatest IRIX, DXR, NYXH, and DRIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/17/2026IRIXIRIDEX Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)7/10/2026DRIODarioHealth Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)7/9/2026NYXHNyxoah Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$2.857/1/2026IRIXIRIDEX Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/24/2026DXRDaxor Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)6/17/2026NYXHNyxoah Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetHold$5.00 ➝ $3.006/16/2026IRIXIRIDEX Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/2/2026IRIXIRIDEX Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/22/2026NYXHNyxoah Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/19/2026IRIXIRIDEX Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/14/2026DRIODarioHealth Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.00 ➝ $10.00(Data available from 7/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDRIODarioHealth$22.36M2.58N/AN/A$10.05 per share0.79DXRDaxorN/AN/AN/AN/AN/AN/AIRIXIRIDEX$52.67M0.30N/AN/A($0.06) per share-15.25NYXHNyxoah$11.33M5.23N/AN/A$1.43 per share1.07Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDRIODarioHealth-$41.71M-$8.88N/AN/AN/A-192.23%-60.52%-37.08%8/11/2026 (Estimated)DXRDaxorN/AN/AN/AN/AN/AN/AN/AN/A8/20/2026 (Estimated)IRIXIRIDEX-$4.44M-$0.19N/AN/AN/A-6.23%N/A-11.16%8/6/2026 (Estimated)NYXHNyxoah-$101.92M-$2.48N/AN/AN/A-543.21%-163.73%-80.24%8/5/2026 (Estimated)Latest IRIX, DXR, NYXH, and DRIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/18/2026Q2 2026IRIXIRIDEX-$0.01N/AN/AN/A$13.59 millionN/A8/11/2026Q2 2026DRIODarioHealth-$0.74N/AN/AN/A$5.92 millionN/A8/5/2026Q2 2026NYXHNyxoah-$0.47N/AN/AN/A$8.64 millionN/A5/19/2026Q1 2026IRIXIRIDEX-$0.07-$0.03+$0.04-$0.03$11.91 million$11.80 million5/12/2026Q1 2026NYXHNyxoah-$0.54-$0.43+$0.11-$0.43$7.05 million$7.38 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthDRIODarioHealthN/AN/AN/AN/AN/ADXRDaxorN/AN/AN/AN/AN/AIRIXIRIDEXN/AN/AN/AN/AN/ANYXHNyxoahN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDRIODarioHealth0.503.072.62DXRDaxorN/AN/AN/AIRIXIRIDEXN/A1.921.19NYXHNyxoah0.530.990.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDRIODarioHealth33.39%DXRDaxor1.34%IRIXIRIDEX20.10%NYXHNyxoahN/AInsider OwnershipCompanyInsider OwnershipDRIODarioHealth3.50%DXRDaxor51.50%IRIXIRIDEX8.60%NYXHNyxoah17.11%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDRIODarioHealth2007.31 million7.06 millionNo DataDXRDaxor375.84 million2.83 millionNot OptionableIRIXIRIDEX12017.41 million15.91 millionOptionableNYXHNyxoah11038.76 million32.13 millionNot OptionableIRIX, DXR, NYXH, and DRIO HeadlinesRecent News About These CompaniesShort Interest in Nyxoah SA (NASDAQ:NYXH) Drops By 63.9%July 13, 2026 | marketbeat.comNyxoah touts Genio US launch traction, reimbursement stability at investor dayJuly 11, 2026 | msn.comNyxoah Touts Genio U.S. Launch Traction, Reimbursement Stability at Investor DayJuly 10, 2026 | marketbeat.comNyxoah SA (NYXH) Analyst/Investor Day TranscriptJuly 8, 2026 | seekingalpha.comNyxoah (ENXTBR:NYXH) Stock Fair Value Moves Lower After Capital Raise And Analyst CautionJuly 8, 2026 | finance.yahoo.comNyxoah reports Q2 2026 preliminary revenue of €7.7MJuly 7, 2026 | msn.comNyxoah Announces Preliminary Results for the Second Quarter of 2026July 7, 2026 | globenewswire.comInformation on the total number of voting rights and sharesJune 30, 2026 | globenewswire.comPublication relating to transparency notificationsJune 29, 2026 | globenewswire.comNyxoah (ENXTBR:NYXH) Stock Fair Value Moves Lower After Analyst Cuts And Capital ConcernsJune 24, 2026 | finance.yahoo.comNyxoah to Host Investor Day in New York on July 8, 2026June 23, 2026 | globenewswire.comNyxoah (NYXH) Gets a Hold from Stifel NicolausJune 23, 2026 | theglobeandmail.comInvitation à assister à l'assemblée générale extraordinaire des actionnaires de la Société qui se tiendra le 9 juillet 2026June 19, 2026 | globenewswire.comInvitation to attend the extraordinary shareholders' meeting of the Company to be held on July 9, 2026June 19, 2026 | globenewswire.comPublication relating to transparency notificationsJune 17, 2026 | globenewswire.comNyxoah Receives $15 Million from the European Investment BankJune 17, 2026 | globenewswire.comNyxoah’s Genio® Wins Prix Galien UK 2026 Award for Best Medical TechnologyJune 16, 2026 | finance.yahoo.comInformation on the total number of voting rights and sharesJune 10, 2026 | globenewswire.com$110 Million in Aggregate Financings to Accelerate Genio's U.S. Commercial LaunchJune 10, 2026 | globenewswire.comNyxoah Announces Closing of Underwritten Public OfferingJune 10, 2026 | globenewswire.comWhat's going on with Nyxoah stock Tuesday?June 9, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIRIX, DXR, NYXH, and DRIO Company DescriptionsDarioHealth NASDAQ:DRIO$7.90 +0.90 (+12.86%) Closing price 04:00 PM EasternExtended Trading$7.44 -0.47 (-5.89%) As of 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Evolve, a metabolic solution to address metabolic health needs, such as diabetes, pre-diabetes, hypertension, and weight management; Dario Move, which address most common musculoskeletal conditions; Dario Elevate, a behavioral health solution that optimizes access to evidence-based care; and Dario One, a full suite of chronic condition management solution; and Dario blood glucose monitoring systems. It also provides native devices, such as glucose meter, blood pressure cuff, digital scale, and biofeedback sensor device, as well as live coaching services. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.Daxor NASDAQ:DXR$11.03 +0.52 (+4.95%) As of 04:00 PM Eastern This is a fair market value price provided by Massive. Learn more.Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation is a subsidiary of Estate Of Joseph Feldschuh.IRIDEX NASDAQ:IRIX$0.92 0.00 (0.00%) Closing price 03:59 PM EasternExtended Trading$0.92 +0.01 (+0.64%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.Nyxoah NASDAQ:NYXH$1.53 -0.01 (-0.65%) Closing price 04:00 PM EasternExtended Trading$1.55 +0.02 (+1.57%) As of 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Robotaxi Mode Engaged: Tesla Starts Monetizing Its Florida Fleet Insider Moves Are Sending Mixed Signals Across the Tech Sector Boxabl Disrupts Housing With A Tiny Float IPO Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying Velo3D Forges a New Reality After Its Sharp Stock Sell-Off Why Apple Could Be the Last One Standing in the Tech Wreck Archer and Anduril Put ACHR Stock on a New Defense Flight Path 3M's Redemption Arc: Can Q2 Earnings Change the Narrative? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
